Efficacy of Tildrakizumab 200 Mg for Treating Difficult-to-Treat Patient Populations With Moderate-to-Severe Plaque Psoriasis. Dermatol Reports 2024, 17 (1). https://doi.org/10.4081/dr.2024.9999.